ClinicalTrials.gg
CompletedNCT01611090Updated Mar 3, 2020Results posted

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 3 interventional study of Ibrutinib and Bendamustine hydrochloride in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 160 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
578
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
2nd of 83
578 · median 44
Started
2012
with 6 others
Phase 3
14 of 83
none open now
Registered
9th of 83
by date
Lead sponsor
8 of 83
Janssen Research & Development, LLC

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 7 that started in 2012, is one of 14 in phase 3, and was the 9th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Read the detailed description

This is a randomized (patients will be assigned by chance to study treatments), double-blind (patients and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL following at least 1 line of prior systemic therapy. Approximately 580 patients will be randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib 420 mg).

Study medication will be administered orally once daily on a continuous schedule. All patients will receive BR as the background therapy plus either ibrutinib or placebo for a maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until disease progression or unacceptable toxicity.

A treatment cycle will be defined as 28 days. The study will include a screening phase, a treatment phase, and a follow-up phase. Study end is defined as when either 80% of the patients have died or 5 years after the last patient is randomized into the study, whichever occurs first.

Patients in treatment arm A (placebo) who complete the treatment phase, with disease progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in treatment arm B), at the investigators discretion. This open-label, next-line treatment with ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from study, or until the study end, whichever occurs earlier. One interim analysis is planned for the study. Efficacy evaluations will include computed tomography scans, laboratory testing, focused physical examinations, bone marrow biopsy and aspirate, and assessment of patient-reported outcomes. In both treatment arms, samples for the development of a population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be collected. Safety will be assessed throughout the study.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
  • Relapsed or refractory chronic lymphocytic leukemia
  • Relapsed or refractory small lymphocytic lymphoma
  • Ibrutinib
  • PCI-32765
  • JNJ-54179060
  • Bruton's tyrosine kinase inhibitor
  • Bendamustine
  • Rituximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets protocol-defined criteria
  • Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic Leukemia 2008 criteria for requiring treatment
  • Measurable nodal disease by computed tomography
  • CLL or SLL following at least 1 consisting of at least 2 cycles of a chemotherapy-containing regimen
  • Performance Status score of 0 or 1
  • Hematology and biochemical values within protocol-defined limits
  • Agrees to protocol-defined use of effective
  • Women of must have negative blood or urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Recent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks (immunotherapy)
  • Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior randomization in any other clinical study evaluating ibrutinib
  • The presence of deletion of the short arm of chromosome 17
  • Patients previously treated with a bendamustine-containing regimen who did not achieve a response or who and required treatment within 24 months of treatment with that regimen
  • Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
  • Received a hematopoietic stem cell transplant
  • Known central nervous system leukemia/lymphoma or Richter's transformation
  • Patients with uncontrolled hemolytic anemia or autoimmune thrombocytopenia
  • Chronic use of
  • History of prior , except: malignancy treated with curative intent and with no known active disease present for >=3 years before randomization; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
  • History of stroke or intracranial hemorrhage within 6 months prior to randomization; or cardiovascular disease
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong /5 inhibitors
  • Known history of or , or active infection with or C
  • Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
  • A woman who is pregnant or breast feeding, or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
578 participants (actual)

Study arms

  • Experimental
    Ibrutinib + BR

    Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).

    Drug: Ibrutinib · Drug: Bendamustine hydrochloride · Drug: Rituximab

  • Placebo comparator
    Placebo + BR

    Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).

    Drug: Bendamustine hydrochloride · Drug: Rituximab · Drug: Placebo

Interventions

  • Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.

  • Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.

  • Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.

  • DrugPlacebo

    Form=capsule, route=oral use. Capsule is taken once daily continuously.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); \>=50% increase in existing lymph nodes; \>=50% increase in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) or \>=50% increase from nadir count confirmed on \>=2 serial assessments if absolute lymphocyte count (ALC) \>=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to CLL; and transformation to a more aggressive histology.

    Time frame: Up to 5 years

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum products of up to 6 lymph nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.

    Time frame: Up to 5 years

  2. Overall Survival (OS)

    OS was defined as the interval between the date of randomization and the date of death from any cause.

    Time frame: Up to 5 years

  3. Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response

    MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia \[CLL\] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.

    Time frame: Up to 5 years

  4. Percentage of Participants With Sustained Hematologic Improvement

    Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.

    Time frame: Up to 5 years

  5. Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

    Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).

    Time frame: Up to 2 years

  6. Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

    The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.

    Time frame: From the date of randomization to disease progression (Up to 2 years)

  7. Number of Participants Who Received Subsequent Antineoplastic Therapy

    Number of participants who received subsequent antineoplastic therapy was reported.

    Time frame: Up to 5 years

  8. Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

    Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.

    Time frame: Baseline to EOT (Up to 2 years)

  9. Change From Baseline in FACIT-Fatigue Scale at End of Treatment

    FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).

    Time frame: Baseline to EOT (up to 2 years)

  10. Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

    EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from "1 = very poor" to "7 = excellent". Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.

    Time frame: Baseline to EOT (up to 2 years)

  11. Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

    The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).

    Time frame: Baseline to EOT (up to 2 years)

  12. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

    The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline to EOT (up to 2 years)

  13. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

    The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.

    Time frame: Baseline to EOT (up to 2 years)

07

Results

Posted Mar 3, 2020
Limitations and caveats
Study was planned to end when 80% of randomized participants died or 5 years after last participant randomized, whichever was first. Sponsor terminated study on 23-Jan-2019 (5 year after last participant randomized) and study was considered completed

Participant flow

Randomized Period
Participant flow — Randomized Period
MilestoneIbrutinib+BRPlacebo+BRCrossover to Ibrutinib
Started2892890
Treated2872870
Completed2592600
Not completed30290
Withdrew: Lost to follow-up830
Withdrew: Withdrawal by subject22260
Cross Over (Placebo to Ibrutinib)
Participant flow — Cross Over (Placebo to Ibrutinib)
MilestoneIbrutinib+BRPlacebo+BRCrossover to Ibrutinib
Started00183
Treated00183
Completed00178
Not completed005
Withdrew: Lost to follow-up004
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes \>1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); \>=50% increase in existing lymph nodes; \>=50% increase in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) or \>=50% increase from nadir count confirmed on \>=2 serial assessments if absolute lymphocyte count (ALC) \>=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to CLL; and transformation to a more aggressive histology.

Time frame:
Up to 5 years
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsIbrutinib+BRPlacebo+BR
Progression-free Survival (PFS)65.12 (55.43 to NA)14.32 (13.86 to 16.62)
Statistical analysis
  • Ibrutinib+BR vs Placebo+BR · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.229 · 95% CI 0.183 to 0.286
SecondaryOverall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: \>=50% decrease in ALC, \>=50% decrease in sum products of up to 6 lymph nodes, \>=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils \>1.5\*10\^9/L, Platelets \>100\*10\^9/L and Hgb\>11 g/dL or \>=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsIbrutinib+BRPlacebo+BR
Overall Response Rate (ORR)87.266.1
SecondaryOverall Survival (OS)

OS was defined as the interval between the date of randomization and the date of death from any cause.

Time frame:
Up to 5 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsIbrutinib+BRPlacebo+BR
Overall Survival (OS)NA (70.93 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD)-Negative Response

MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia \[CLL\] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response
Percentage of participantsIbrutinib+BRPlacebo+BR
Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response28.75.9
SecondaryPercentage of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.

Time frame:
Up to 5 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Hematologic Improvement
Percentage of ParticipantsIbrutinib+BRPlacebo+BR
Hemoglobin36.729.1
Platelets30.821.8
SecondaryMedian Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).

Time frame:
Up to 2 years
Reported as:
Number · Months
Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale
MonthsIbrutinib+BRPlacebo+BR
Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale6.5 (4.7 to 10.7)4.6 (2.8 to 6.4)
SecondaryNumber of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.

Time frame:
From the date of randomization to disease progression (Up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms
ParticipantsIbrutinib+BRPlacebo+BR
Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms00
SecondaryNumber of Participants Who Received Subsequent Antineoplastic Therapy

Number of participants who received subsequent antineoplastic therapy was reported.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants Who Received Subsequent Antineoplastic Therapy
ParticipantsIbrutinib+BRPlacebo+BR
Number of Participants Who Received Subsequent Antineoplastic Therapy5261
SecondaryChange From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.

Time frame:
Baseline to EOT (Up to 2 years)
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)
milligram per liter (mg/L)Ibrutinib+BRPlacebo+BR
Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)-0.46 ± 1.77-0.23 ± 2.08
SecondaryChange From Baseline in FACIT-Fatigue Scale at End of Treatment

FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).

Time frame:
Baseline to EOT (up to 2 years)
Reported as:
Mean · Units on a scale
Change From Baseline in FACIT-Fatigue Scale at End of Treatment
Units on a scaleIbrutinib+BRPlacebo+BR
Change From Baseline in FACIT-Fatigue Scale at End of Treatment-0.9 ± 11.220.0 ± 11.01
SecondaryChange From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from "1 = very poor" to "7 = excellent". Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.

Time frame:
Baseline to EOT (up to 2 years)
Reported as:
Mean · Units on a scale
Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment
Units on a scaleIbrutinib+BRPlacebo+BR
Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment-2.1 ± 16.34-4.1 ± 22.52
SecondaryChange From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).

Time frame:
Baseline to EOT (up to 2 years)
Reported as:
Mean · Units on the scale
Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment
Units on the scaleIbrutinib+BRPlacebo+BR
Lost weight0.1 ± 0.860.0 ± 0.74
Dry mouth0.3 ± 0.960.1 ± 0.85
Bruises0.1 ± 0.610.0 ± 0.65
Abdominal discomfort0.1 ± 0.810.0 ± 0.76
Temperature going up and down0.1 ± 0.930.0 ± 0.72
Night sweats-0.6 ± 0.92-0.3 ± 1.07
Skin problems0.4 ± 1.140.3 ± 0.96
Feel ill0.1 ± 1.080.2 ± 0.98
Feel lethargic0.1 ± 1.010.0 ± 0.91
Felt slowed down0.3 ± 0.800.0 ± 0.97
Limited in planning activities0.2 ± 0.970.1 ± 0.90
Worried about health in the future0.0 ± 0.940.0 ± 0.97
Trouble with chest infections0.2 ± 1.050.0 ± 0.82
Trouble with other infections0.7 ± 1.070.1 ± 0.86
Repeated courses of antibiotics0.9 ± 1.220.0 ± 0.97
Worried about picking up infection0.3 ± 0.960.2 ± 1.00
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).

Time frame:
Baseline to EOT (up to 2 years)
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment
Units on a scaleIbrutinib+BRPlacebo+BR
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment-4.3 ± 19.584.0 ± 18.21
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.

Time frame:
Baseline to EOT (up to 2 years)
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment
Units on a scaleIbrutinib+BRPlacebo+BR
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment0.0 ± 0.280.0 ± 0.24

Adverse events

Collected over From the time a signed and dated informed consent form is obtained until 30 days following the last dose of study treatment or until the start of a subsequent systemic antineoplastic therapy, if earlier (up to 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib+BR74/287 (25.8%)198/287 (69%)268/287 (93.4%)
Placebo+BR107/287 (37.3%)127/287 (44.3%)271/287 (94.4%)
Crossover to Ibrutinib57/183 (31.1%)105/183 (57.4%)157/183 (85.8%)
Most frequent serious events
Showing 10 of 364
Most frequent serious events
EventIbrutinib+BRPlacebo+BRCrossover to Ibrutinib
PneumoniaInfections and infestations48/28726/28734/183
Febrile NeutropeniaBlood and lymphatic system disorders30/28722/2872/183
Atrial FibrillationCardiac disorders16/2872/2876/183
PyrexiaGeneral disorders11/2877/2874/183
BronchitisInfections and infestations8/2875/2871/183
SepsisInfections and infestations8/2874/2874/183
Respiratory Tract InfectionInfections and infestations5/2872/2875/183
Septic ShockInfections and infestations6/2872/2875/183
AnaemiaBlood and lymphatic system disorders3/2877/2872/183
NeutropeniaBlood and lymphatic system disorders7/2876/2870/183
Most frequent other events
Showing 10 of 73
Most frequent other events
EventIbrutinib+BRPlacebo+BRCrossover to Ibrutinib
NeutropeniaBlood and lymphatic system disorders170/287159/28740/183
DiarrhoeaGastrointestinal disorders115/28768/28747/183
NauseaGastrointestinal disorders108/287101/28716/183
ThrombocytopeniaBlood and lymphatic system disorders90/28769/28724/183
AnaemiaBlood and lymphatic system disorders73/28779/28733/183
CoughRespiratory, thoracic and mediastinal disorders74/28775/28727/183
PyrexiaGeneral disorders74/28760/28722/183
FatigueGeneral disorders69/28766/28732/183
Upper Respiratory Tract InfectionInfections and infestations69/28750/28736/183
Infusion Related ReactionInjury, poisoning and procedural complications45/28764/2871/183

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibrutinib+BRPlacebo+BRTotal
Mean63.7 ± 9.8263.3 ± 9.363.5 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib+BRPlacebo+BRTotal
Female96100196
Male193189382
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib+BRPlacebo+BRTotal
Hispanic or Latino132134
Not Hispanic or Latino256253509
Unknown or Not Reported201535
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibrutinib+BRPlacebo+BRTotal
White264264528
Black8614
Asian123
American Indian or Alaska Native112
Native Hawaiian or other Pacific Islander000
Other3710
Unknown or not reported12921
Region of Enrollment
Region of Enrollment(Participants)Ibrutinib+BRPlacebo+BRTotal
ARGENTINA336
BELGIUM141428
BRAZIL101222
CANADA273562
COLOMBIA011
CZECH REPUBLIC121123
FRANCE161127
GERMANY101121
GREECE12517
ISRAEL141226
MEXICO123
POLAND192039
PORTUGAL71219
RUSSIAN FEDERATION5050100
SOUTH KOREA011
SPAIN9918
SWEDEN246
TURKEY242751
UKRAINE161430
UNITED KINGDOM5914
UNITED STATES382664
08

Study locations

160 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Berkeley, California, United States
  • Duarte, California, United States
  • Greenbrae, California, United States
  • Stamford, Connecticut, United States
  • Washington, District of Columbia, United States
  • Boca Raton, Florida, United States
  • Jacksonville, Florida, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Springfield, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Goshen, Indiana, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Westwood, Kansas, United States
  • Louisville, Kentucky, United States
  • Paducah, Kentucky, United States
  • Marrero, Louisiana, United States
  • Baltimore, Maryland, United States
  • Worcester, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Battle Creek, Michigan, United States
  • Detroit, Michigan, United States
  • Lansing, Michigan, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Hackensack, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Dunkirk, New York, United States
  • Hawthorne, New York, United States
  • New York, New York, United States
  • Bismarck, North Dakota, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Temple, Texas, United States
  • Morgantown, West Virginia, United States
  • Buenos Aires, Argentina
  • Ciudad Autonoma Buenos Aires, Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina
  • Cordoba, Argentina
  • Aalst, Belgium
  • Brugge, Belgium
  • Brussels, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Edmonton, Alberta, Canada
  • Vancouver N/a, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Bogota, Colombia
  • Floridablanca, Colombia
  • Brno, Czechia
  • Praha 10, Czechia
  • Praha 2, Czechia
  • Creteil, France
  • Montpellier, France
  • Paris Cedex 13, France
  • Pessac, France
  • Pierre Benite, France
  • Tours, France
  • Villejuif, France
  • Aschaffenburg, Germany
  • Augsburg, Germany
  • Dresden, Germany
  • Erlangen, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Frechen, Germany
  • Hamm, Germany
  • Heidelberg, Germany
  • Homburg/Saar, Germany
  • Kassel, Germany
  • Kiel, Germany
  • Koblenz, Germany
  • Köln, Germany
  • Kÿln N/a, Germany
  • Lebach, Germany
  • Magdeburg, Germany
  • Mannheim, Germany
  • Marburg, Germany
  • Mutlangen, Germany
  • Ulm, Germany
  • Würzburg, Germany
  • Athens, Greece
  • Thessalonikis, Greece
  • Haifa, Israel
  • Jerusalem, Israel
  • Nahariya, Israel

Showing the first 100 of 160 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2020 Dec;61(13):3188-3197. doi: 10.1080/10428194.2020.1795159. Epub 2020 Aug 6. PubMed 32762271 ↗
  • Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8. PubMed 31044267 ↗
  • Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. PubMed 28751558 ↗
  • Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5. PubMed 26655421 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Jan 2019, 76 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 76 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2012
First posted
Jun 4, 2012
StartActual
Sep 19, 2012
Primary completionActual
Jan 23, 2019
CompletionActual
Jan 23, 2019
Results first posted
Mar 3, 2020
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01611090
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jun 4, 2012
Start date
Sep 19, 2012
Primary completion
Jan 23, 2019
Completion
Jan 23, 2019
Results posted
Mar 3, 2020
Last update
Mar 3, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion